Thus, by inhibiting the tyrosine kinase activity of ABL1, Imatinib enhances TGF-β-mediated growth inhibition and apoptosis in CML cells, which is beneficial for patients with CML. Here, TGFB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.